Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Horizon Discovery Group Launches Collection of Highly Characterized Patient-Derived Xenograft Models of Breast Cancer under SAGE Labs Brand

publication date: Nov 21, 2014
 | 
author/source: Horizon Discovery

Largest available collection of PDX cell lines, faithfully modelling human breast cancers

horizonHorizon Discovery Group plc (Horizon), a leading provider of products, services and technologies in the field of genome engineering, today announced the launch of its Patient-Derived Xenograft (PDX) models of breast cancer under its SAGE Labs brand. The new panel is the largest available collection of highly characterized PDX models, and is licensed from Washington University.

The collection comprises a broad range of PDX lines, which allow the study of human tumors in an in vivo model system. PDX models are a key tool in the development of personalized medicines. The lines accurately model real patient tumors, enabling researchers to discover important genetic differences, develop biomarkers to distinguish them, and ultimately develop patient-specific therapies.

The new collection includes ten triple negative lines, as well as several ER+ (estrogen receptor positive) lines. Whole genome sequencing has been performed on the originating tumors, early and late passages of PDX, as well as metastases, demonstrating striking similarity and faithful modeling of the original tumor, with all contaminating mouse signal removed. Using SAGE Labs’ PDXplorer, customers can access a wealth of data on the PDX models, including comprehensive patient histories, estradiol responsiveness, RNAseq profiles, DNA microarrays, and phosphoprotein profiles, and can handpick the models that best support their research.  

Dr David Smoller, Chief Business Officer, Horizon, commented:“Patient-derived xenografts are highly translational and relevant models of human cancers, and have been invaluable tools for oncology research. However, their utility has previously been somewhat limited by incomplete characterization. SAGE Labs’ new collection of PDX breast cancer models, sourced from the labs of Drs. Matt Ellis and Shunqiang Li at Washington University, is highly characterized, unlocking their full potential and making them an exciting addition to Horizon’s offering.”


more about horizon discovery group 




 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events